LC-MS/MS determination of the HIV-1 protease inhibitor indinavir in brain and testis of mice

被引:4
作者
de Oliveira, MP
Venisse, N
Couet, W
Olivier, JC
机构
[1] Fac Med & Pharm, EA Pharmacol Medicaments Anti Infectieux 3809, F-86022 Poitiers, France
[2] Ctr Hosp Univ Poitiers, Lab Pharmacocinet, Fac Med & Pharm, F-86022 Poitiers, France
关键词
indinavir; amprenavir; LC-MS/MS; solid-phase extraction; brain; testis;
D O I
10.1016/j.jpba.2005.07.008
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A rapid and sensitive method for the determination of indinavir in mice brain and testis is described and validation data are provided. Indinavir and the internal standard (IS) amprenavir were isolated from homogenized tissue matrices using a mixed-mode solid-phase extraction (SPE) procedure and were then analyzed by reversed-phase liquid chromatography/tandem mass spectrometry (LC-MS/MS). The mass spectrometer in the positive-ion multiple reaction monitoring mode used pairs of ions at m/z of 614.1/421.3 for indinavir and of 506.1/245.3 for IS. The calibration curves were linear over the range 0.0012-0.0390 mu mol/kg for brain and 0.39-12.50 mu mol/kg for testis. Linearity, repeatability and accuracy were validated. The applicability of the method was demonstrated by assessing indinavir in brain and testis of three mice dosed with intravenous bolus administration of indinavir (16.3 mu mol/ka). (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:353 / 359
页数:7
相关论文
共 27 条
[11]   Structural elucidation of metabolites of ritonavir and indinavir by liquid chromatography-mass spectrometry [J].
Gangl, E ;
Utkin, I ;
Gerber, N ;
Vouros, P .
JOURNAL OF CHROMATOGRAPHY A, 2002, 974 (1-2) :91-101
[12]   Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir [J].
Hugen, PWH ;
Burger, DM ;
de Graaff, M ;
ter Hofstede, HJM ;
Hoetelmans, RMW ;
Brinkman, K ;
Meenhorst, PL ;
Mulder, JW ;
Koopmans, PP ;
Hekster, YA .
THERAPEUTIC DRUG MONITORING, 2000, 22 (04) :437-445
[13]   An LC-MS-MS method for the determination of indinavir, an HIV-1 protease inhibitor, in human plasma [J].
Jayewardene, AL ;
Kearney, B ;
Stone, JA ;
Gambertoglio, JG ;
Aweeka, FT .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2001, 25 (02) :309-317
[14]   Drug concentration heterogeneity facilitates the evolution of drug resistance [J].
Kepler, TB ;
Perelson, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :11514-11519
[15]   The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors [J].
Kim, RB ;
Fromm, MF ;
Wandel, C ;
Leake, B ;
Wood, AJJ ;
Roden, DM ;
Wilkinson, GR .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) :289-294
[16]   Protease inhibitors: A therapeutic breakthrough for the treatment of patients with human immunodeficiency virus [J].
Lewis, JS ;
Terriff, CM ;
Coulston, DR ;
Garrison, MW .
CLINICAL THERAPEUTICS, 1997, 19 (02) :187-214
[17]   Intestinal metabolism promotes regional differences in apical uptake of indinavir: Coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat [J].
Li, LLY ;
Amidon, GL ;
Kim, JS ;
Heimbach, T ;
Kesisoglou, F ;
Topliss, JT ;
Fleisher, D .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (02) :586-593
[18]   Simultaneous high-performance liquid chromatographic determination of a glucuronyl prodrug of doxorubicin, doxorubicin and its metabolites in human lung tissue [J].
Mürdter, TE ;
Sperker, B ;
Bosslet, K ;
Fritz, P ;
Kroemer, HK .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1998, 709 (02) :289-295
[19]   High-performance liquid chromatographic method for the disposition of mazindol and its metabolite 2-(2-aminoethyl)-3-(p-chlorophenyl)-3-hydroxyphthalimidine in mouse brain and plasma [J].
Nakashima, K ;
Kaddoumi, A ;
Mori, M ;
Nakashima, MN ;
Wada, M ;
Aboul-Enein, HY .
ANALYTICA CHIMICA ACTA, 2004, 502 (01) :39-47
[20]   Reservoirs of human immunodeficiency virus type 1: The main obstacles to viral eradication [J].
Pomerantz, RJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :91-97